Esperion Therapeutics, Inc. — Director's Dealing 2021

Nov 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2021-10-29

Reporting Person: Koenig Sheldon L. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-29	Common Stock	A	26700	—	Acquired	76700	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$8.94	2031-10-29	Common Stock (37850.0)	37850	Direct

Footnotes

F1: The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label.